251 related articles for article (PubMed ID: 29990957)
1. Advanced cellular systems to study tuberculosis treatment.
Bielecka MK; Elkington P
Curr Opin Pharmacol; 2018 Oct; 42():16-21. PubMed ID: 29990957
[TBL] [Abstract][Full Text] [Related]
2. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
3. Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery.
de Wet TJ; Warner DF; Mizrahi V
Acc Chem Res; 2019 Aug; 52(8):2340-2348. PubMed ID: 31361123
[TBL] [Abstract][Full Text] [Related]
4. Recent updates on drug resistance in Mycobacterium tuberculosis.
Singh R; Dwivedi SP; Gaharwar US; Meena R; Rajamani P; Prasad T
J Appl Microbiol; 2020 Jun; 128(6):1547-1567. PubMed ID: 31595643
[TBL] [Abstract][Full Text] [Related]
5. SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.
Poce G; Cocozza M; Consalvi S; Biava M
Eur J Med Chem; 2014 Oct; 86():335-51. PubMed ID: 25173852
[TBL] [Abstract][Full Text] [Related]
6. Transcriptomic Signatures Predict Regulators of Drug Synergy and Clinical Regimen Efficacy against Tuberculosis.
Ma S; Jaipalli S; Larkins-Ford J; Lohmiller J; Aldridge BB; Sherman DR; Chandrasekaran S
mBio; 2019 Nov; 10(6):. PubMed ID: 31719182
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of Multi-Drug Resistant
Ali S; Khan MT; Khan AS; Mohammad N; Khan MM; Ahmad S; Noor S; Jabbar A; Daire C; Hassan F
Pol J Microbiol; 2020; 69(2):1-5. PubMed ID: 32249555
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and bioactivity of antitubercular peptides and peptidomimetics: an update.
De Leon Rodriguez LM; Kaur H; Brimble MA
Org Biomol Chem; 2016 Jan; 14(4):1177-87. PubMed ID: 26645944
[TBL] [Abstract][Full Text] [Related]
9. Clinical Management of Drug-resistant Mycobacterium tuberculosis Strains: Pathogen-targeted Versus Host-directed Treatment Approaches.
Al-Ghafli H; Al-Hajoj S
Curr Pharm Biotechnol; 2019; 20(4):272-284. PubMed ID: 30062961
[TBL] [Abstract][Full Text] [Related]
10. New treatment options for multidrug-resistant tuberculosis.
Field SK; Fisher D; Jarand JM; Cowie RL
Ther Adv Respir Dis; 2012 Oct; 6(5):255-68. PubMed ID: 22763676
[TBL] [Abstract][Full Text] [Related]
11. Novel candidates in the clinical development pipeline for TB drug development and their synthetic approaches.
Kumar A; Karkara BB; Panda G
Chem Biol Drug Des; 2021 Nov; 98(5):787-827. PubMed ID: 34397161
[TBL] [Abstract][Full Text] [Related]
12. Isoniazid derivatives and their anti-tubercular activity.
Hu YQ; Zhang S; Zhao F; Gao C; Feng LS; Lv ZS; Xu Z; Wu X
Eur J Med Chem; 2017 Jun; 133():255-267. PubMed ID: 28390957
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in the research of heterocyclic compounds as antitubercular agents.
Yan M; Ma S
ChemMedChem; 2012 Dec; 7(12):2063-75. PubMed ID: 23042656
[TBL] [Abstract][Full Text] [Related]
14. Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis.
Eshetie S; Gizachew M; Dagnew M; Kumera G; Woldie H; Ambaw F; Tessema B; Moges F
BMC Infect Dis; 2017 Mar; 17(1):219. PubMed ID: 28320336
[TBL] [Abstract][Full Text] [Related]
15. Advances in Key Drug Target Identification and New Drug Development for Tuberculosis.
Mi J; Gong W; Wu X
Biomed Res Int; 2022; 2022():5099312. PubMed ID: 35252448
[TBL] [Abstract][Full Text] [Related]
16. Remembering the Host in Tuberculosis Drug Development.
Frank DJ; Horne DJ; Dutta NK; Shaku MT; Madensein R; Hawn TR; Steyn AJC; Karakousis PC; Kana BD; Meintjes G; Laughon B; Tanvir Z
J Infect Dis; 2019 Apr; 219(10):1518-1524. PubMed ID: 30590592
[TBL] [Abstract][Full Text] [Related]
17. Tuberculosis treatment-shortening.
Singh V
Drug Discov Today; 2024 May; 29(5):103955. PubMed ID: 38548262
[TBL] [Abstract][Full Text] [Related]
18. Identification of glucosyl-3-phosphoglycerate phosphatase as a novel drug target against resistant strain of Mycobacterium tuberculosis (XDR1219) by using comparative metabolic pathway approach.
Uddin R; Zahra NU; Azam SS
Comput Biol Chem; 2019 Apr; 79():91-102. PubMed ID: 30743161
[TBL] [Abstract][Full Text] [Related]
19. New perspectives on the treatment of mycobacterial infections using antibiotics.
He Y; Fan A; Han M; Zhang Y; Tong Y; Zheng G; Zhu S
Appl Microbiol Biotechnol; 2020 May; 104(10):4197-4209. PubMed ID: 32185432
[TBL] [Abstract][Full Text] [Related]
20. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
